These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 38107838)

  • 1. Clinical characterization and outcomes of a cohort of colombian patients with AL Amyloidosis.
    Lacouture Fierro JA; Ribero Vargas DA; Sánchez Cano J; Gaviria Jaramillo LM; Perilla Suarez OG; Galvez Cárdenas KM; Ospina Ospina S
    Colomb Med (Cali); 2023; 54(3):e2025667. PubMed ID: 38107838
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Outcomes from Autologous Hematopoietic Cell Transplantation versus Chemotherapy Alone for the Management of Light Chain Amyloidosis.
    Oke O; Sethi T; Goodman S; Phillips S; Decker I; Rubinstein S; Concepcion B; Horst S; Jagasia M; Kassim A; Harrell SL; Langone A; Lenihan D; Rawling KT; Slosky D; Cornell RF
    Biol Blood Marrow Transplant; 2017 Sep; 23(9):1473-1477. PubMed ID: 28546074
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Autologous stem cell transplantation vs bortezomib based chemotheraphy for the first-line treatment of systemic light chain amyloidosis in the UK.
    Sharpley FA; Manwani R; Petrie A; Mahmood S; Sachchithanantham S; Lachmann HJ; Martinez De Azcona Naharro A; Gillmore JD; Whelan CJ; Fontana M; Cohen O; Hawkins PN; Wechalekar AD
    Eur J Haematol; 2021 Apr; 106(4):537-545. PubMed ID: 33460466
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Outcomes of autologous stem cell transplant for cardiac AL-amyloidosis and cardiac light chain deposition disease.
    Abdallah AA; Alapat D; Kaur V; Atrash S
    J Oncol Pharm Pract; 2020 Jul; 26(5):1128-1133. PubMed ID: 31795821
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vincristine, Doxorubicin, and Dexamethasone Induction before Autologous Stem Cell Transplantation in Patients with AL Amyloidosis: A Retrospective Comparison with Frontline Stem Cell Transplantation.
    Iijima T; Sawa N; Nakayama Y; Oba Y; Ikuma D; Mizuno H; Yamanouchi M; Suwabe T; Wake A; Kono K; Hoshino J; Ubara Y; Ohashi K
    Intern Med; 2022 Oct; 61(19):2853-2860. PubMed ID: 35228429
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment With Bortezomib-based Therapy, Followed by Autologous Stem Cell Transplantation, Improves Outcomes in Light Chain Amyloidosis: A Retrospective Study.
    Jain T; Kosiorek HE; Kung ST; Shah VS; Dueck AC; Gonzalez-Calle V; Luft S; Reeder CB; Adams R; Noel P; Larsen JT; Mikhael J; Bergsagel L; Stewart AK; Fonseca R
    Clin Lymphoma Myeloma Leuk; 2018 Jul; 18(7):486-492.e1. PubMed ID: 29753692
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Induction Therapy with Bortezomib and Dexamethasone and Conditioning with High-Dose Melphalan and Bortezomib Followed by Autologous Stem Cell Transplantation for Immunoglobulin Light Chain Amyloidosis: Long-Term Follow-Up Analysis.
    Gupta VK; Brauneis D; Shelton AC; Quillen K; Sarosiek S; Sloan JM; Sanchorawala V
    Biol Blood Marrow Transplant; 2019 May; 25(5):e169-e173. PubMed ID: 30639823
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A real-life cohort study of immunoglobulin light-chain (AL) amyloidosis patients ineligible for autologous stem cell transplantation due to severe cardiac involvement or advanced disease.
    Brunger AF; Nienhuis HLA; Bijzet J; Roeloffzen WWH; Vellenga E; Hazenberg BPC
    Amyloid; 2020 Jun; 27(2):119-127. PubMed ID: 32052655
    [No Abstract]   [Full Text] [Related]  

  • 9. The role of induction therapy before autologous stem cell transplantation in low disease burden AL amyloidosis patients.
    Huang X; Ren G; Chen W; Guo J; Zhao L; Zeng C; Ge Y; Liu Z
    Amyloid; 2021 Jun; 28(2):75-83. PubMed ID: 33084412
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Complete remission of both immunoglobulin light chain amyloidosis and psoriasis after autologous hematopoietic stem cell transplantation: A case report.
    Chen W; Ren G; Zuo K; Huang X
    Medicine (Baltimore); 2018 Dec; 97(50):e13589. PubMed ID: 30558027
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk factors, treatments and outcomes of patients with light chain amyloidosis who relapse after autologous stem cell transplantation.
    Zhang Y; Guo J; Chen W; Zhao L; Huang X
    Bone Marrow Transplant; 2024 Mar; 59(3):350-358. PubMed ID: 38148411
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A retrospective analysis of clinical features and treatment outcome in 21 patients with immunoglobulin M-related light-chain amyloidosis in Japan: a study from the Amyloidosis Research Committee.
    Fuchida SI; Ogura M; Ishida T; Hata H; Handa H; Katoh N; Nakaseko C; Sunami K; Katayama Y; Nobata H; Oshiro K; Iida S; Sekijima Y; Naiki H; Shimazaki C
    Int J Hematol; 2023 Oct; 118(4):443-449. PubMed ID: 37515656
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Retrospective Analysis of Autologous Stem Cell Transplantation for AL Amyloidosis: A Study from the Multiple Myeloma Working Group of the Japan Society for Hematopoietic Cell Transplantation.
    Fuchida SI; Kawamura K; Sunami K; Tsukada N; Fujii S; Ohkawara H; Usuki K; Wake A; Endo S; Ishiyama K; Ueda Y; Nakamura Y; Miyamoto T; Fukuda T; Ichinohe T; Atsuta Y; Takamatsu H
    Transplant Cell Ther; 2022 Feb; 28(2):76-82. PubMed ID: 34774818
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Management of AL amyloidosis in 2020.
    Palladini G; Milani P; Merlini G
    Hematology Am Soc Hematol Educ Program; 2020 Dec; 2020(1):363-371. PubMed ID: 33275753
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical features, laboratory characteristics and outcomes of patients with renal versus cardiac light chain amyloidosis.
    Sidana S; Tandon N; Gertz MA; Dispenzieri A; Ramirez-Alvarado M; Murray DL; Kourelis TV; Buadi FK; Kapoor P; Gonsalves W; Warsame R; Lacy MQ; Kyle RA; Rajkumar SV; Kumar SK; Leung N
    Br J Haematol; 2019 May; 185(4):701-707. PubMed ID: 30836444
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of amyloid light chain cardiac amyloidosis: systematic review and future directions.
    Alsomali D; Mohty D; Grogan M; Dispenzieri A; Aljurf M; Kumar S; Gertz MA; Hanbali A; Hashmi SK
    Clin Adv Hematol Oncol; 2022 Oct; 20(10):609-618. PubMed ID: 36206073
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Management of AL amyloidosis in 2020.
    Palladini G; Milani P; Merlini G
    Blood; 2020 Dec; 136(23):2620-2627. PubMed ID: 33270858
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Induction bortezomib in Al amyloidosis followed by high dose melphalan and autologous stem cell transplantation: a single institution retrospective study.
    Scott EC; Heitner SB; Dibb W; Meyers G; Smith SD; Abar F; Kovacsovics T; Perez-Avraham G; Stentz A; Frires R; Dibb J; Maziarz RT
    Clin Lymphoma Myeloma Leuk; 2014 Oct; 14(5):424-430.e1. PubMed ID: 24650974
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Daratumumab, pomalidomide, and dexamethasone as a bridging therapy to autologous stem cell transplantation in a case of systemic light-chain amyloidosis with advanced cardiac involvement.
    Arnall JR; Usmani SZ; Adamu H; Mishkin J; Bhutani M
    J Oncol Pharm Pract; 2019 Jun; 25(4):1021-1025. PubMed ID: 30477388
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Outcome of Cardiac Light-Chain Amyloidosis in the Era of Novel Therapy　- A Single-Center Cohort Study of 227 Patients.
    Feng J; Zhang C; Shen K; Sun J; Fang Q; Zhang L; Cao X; Zhou D; Li J; Tian Z
    Circ J; 2019 Mar; 83(4):775-782. PubMed ID: 30773521
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.